文献速递艾滋病与性传播感染

模拟治疗依从性对HIV耐药传播的影响

Modelling the impact of treatment adherence on the transmission of HIV drug resistance.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

该研究建立动态传播模型,纳入CD4计数依赖的诊断、治疗和依从率及传播性/获得性耐药,用2008-2018年广西HIV/AIDS监测数据校准验证。模拟显示依从性降低可抵消扩大ART的收益并加剧耐药传播。

要点

  • 基线(依从性90%、覆盖率79%)下2022-2050年累计新发感染420539例、耐药感染34751例、HIV相关死亡321671例。
  • 覆盖率升至95%可减少新发感染18.85%、死亡15.75%,但依从性90%/80%时耐药感染分别增加11.66%/32.98%。
  • 依从性降至57.08%以下可抵消覆盖率升至95%减少感染的收益,降至40.84%以下可抵消减少死亡的收益。

核心结论

  • 依从性下降可能抵消扩大ART的收益并加剧耐药传播,确保治疗患者依从性可能与扩大ART至未治疗者同样重要。

研究设计与样本

  • 建立动态传播模型,纳入CD4计数依赖的诊断率、治疗率和依从率及传播性耐药(TDR)和获得性耐药。
  • 模型分别用2008-2018年广西HIV/AIDS监测数据和初诊未治疗者TDR患病率进行校准与验证。

主要发现

  • 基线(ART依从性90%、覆盖率79%)下,预测2022-2050年累计新发感染420539例、新发耐药感染34751例、HIV相关死亡321671例。
  • 覆盖率升至95%可减少新发感染18.85%、减少死亡15.75%。
  • 依从性降至57.08%以下可抵消覆盖率升至95%减少感染的收益,降至40.84%以下可抵消减少死亡的收益。
  • 依从性每降低10%,需覆盖率增加5.07%(避免感染增加)或3.62%(避免死亡增加)。
  • 覆盖率升至95%时,依从性90%使耐药感染增加11.66%,依从性80%使耐药感染增加32.98%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: A lower adherence rate (percentage of individuals taking drugs as prescribed) to ART may increase the risk of emergence and transmission of HIV drug resistance, decrease treatment efficacy, and increase mortality rate. Exploring the impact of ART adherence on the transmission of drug resistance could provide insights in controlling the HIV epidemic. METHODS: We proposed a dynamic transmission model incorporating the CD4 cell count-dependent rates of diagnosis, treatment and adherence with transmitted drug resistance (TDR) and acquired drug resistance. This model was calibrated and validated by 2008-2018 HIV/AIDS surveillance data and prevalence of TDR among newly diagnosed treatment-naive individuals from Guangxi, China, respectively. We aimed to identify the impact of adherence on drug resistance and deaths during expanding ART. RESULTS: In the base case (ART at 90% adherence and 79% coverage), we projected the cumulative total new infections, new drug-resistant infections, and HIV-related deaths between 2022 and 2050 would be 420 539, 34 751 and 321 671. Increasing coverage to 95% would reduce the above total new infections (deaths) by 18.85% (15.75%). Reducing adherence to below 57.08% (40.84%) would offset these benefits of increasing coverage to 95% in reducing infections (deaths). Every 10% decrease in adherence would need 5.07% (3.62%) increase in coverage to avoid an increase in infections (deaths). Increasing coverage to 95% with 90% (80%) adherence would increase the above drug-resistant infections by 11.66% (32.98%). CONCLUSIONS: A decrease in adherence might offset the benefits of ART expansion and exacerbate the transmission of drug resistance. Ensuring treated patients' adherence might be as important as expanding ART to untreated individuals.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lai H, Li R, Li Z, et al. Modelling the impact of treatment adherence on the transmission of HIV drug resistance. J Antimicrob Chemother. 2023. PMID: 37311203. doi:10.1093/jac/dkad186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。